Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)

PHASE3CompletedINTERVENTIONAL
Enrollment

277

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

April 7, 2025

Study Completion Date

June 10, 2025

Conditions
Active Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

Anifrolumab

Intravenous infusion (IV)

DRUG

placebo

Intravenous infusion (IV)

Trial Locations (65)

114

Research Site, Taipei

220

Research Site, New Taipei City

333

Research Site, Taoyuan District

1000

Research Site, Manila

1112

Research Site, Quezon City

4217

Research Site, Lipa City

5000

Research Site, Iloilo City

6591

Research Site, Seoul

10400

Research Site, Bangkok

11220

Research Site, Taipei

16499

Research Site, Suwon

23561

Research Site, New Taipei City

40447

Research Site, Taichung

40705

Research Site, Taichung

81362

Research Site, Kaohsiung City

100029

Research Site, Beijing

100034

Research Site, Beijing

100144

Research Site, Beijing

100191

Research Site, Beijing

100730

Research Site, Beijing

110001

Research Site, Shenyang

110004

Research Site, Shengyang

130012

Research Site, Chuangchun

200025

Research Site, Shanghai

210008

Research Site, Nanjing

214002

Research Site, Wuxi

215006

Research Site, Suzhou

233004

Research Site, Bengbu

250012

Research Site, Jinan

256603

Research Site, Binzhou

272011

Research Site, Jining

276003

Research Site, Linyi

277102

Research Site, Zaozhuang

300050

Research Site, Tianjin

310006

Research Site, Hangzhou

325000

Research Site, Wenzhou

330006

Research Site, Nanchang

361003

Research Site, Xiamen

410008

Research Site, Changsha

421001

Research Site, Hengyang

430022

Research Site, Wuhan

430030

Research Site, Wuhan

450052

Research Site, Zhengzhou

453002

Research Site, Xinxiang

471003

Research Site, Luoyang

473005

Research Site, Nanyang

510080

Research Site, Guangzhou

510260

Research Site, Guangzhou

518020

Research Site, Shenzhen

522000

Research Site, Jieyang

541001

Research Site, Guilin

637000

Research Site, Nanchong

650032

Research Site, Kunming

730000

Research Site, Lanzhou

750004

Research Site, Yinchuan

831118

Research Site, Ürümqi

071000

Research Site, Baoding

014010

Research Site, Baotou

Unknown

Research Site, Changchun

Research Site, Hong Kong

050001

Research Site, Shijiazhuang

00000

Research Site, Hong Kong

PH-8000

Research Site, Davao City

501-757

Research Site, Gwangju

04763

Research Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY